* Remains focused on growth
* Expects full-year 2012 sales of $3.1 billion
By Deena Beasley
SAN FRANCISCO, Jan 8 Eye care company Bausch &
Lomb is focused on future growth at the same time it is
"aspiring to return to public markets," Chief Executive Officer
Brent Saunders said following a presentation here.
He declined to comment on reports that Warburg Pincus, which
took the company private in 2007 for about $4.5 billion,
including $830 million in debt, is looking for buyers willing to
pay more than $10 billion for the eye care company.
Sources have also said the private equity firm could turn to
an initial public offering (IPO) as an alternative.
"We are aspiring to return to public markets," Saunders said
on the sidelines of the J.P. Morgan Healthcare Conference on
Bausch & Lomb expects to post record sales of $3.1 billion
for 2012, according to the CEO.
Full-year earnings before interest, taxes, depreciation and
amortization are expected to total around $640 million.
Industry sources here at the conference have mentioned
companies including Johnson & Johnson, Abbott
Laboratories, Sanofi and Merck & Co Inc
as potential buyers of Bausch & Lomb.
Founded in 1853, Rochester, New York-based Bausch & Lomb
makes contact lenses, eye drugs and surgical equipment and sells
its products in more than 100 countries.
The company has undergone a transformation under Saunders,
who joined in March 2010 and has built up the business through
acquisitions, most recently taking over Germany's Technolas
Perfect Vision GmbH, an eye laser firm, in November.